Compare Eli Lilly And Co (LLY) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Eli Lilly And Co trades at $1,158.75 (market cap $1.02T), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.68. The key difference: Eli Lilly And Co pays a 0.6% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals.
| LLY | VNQI | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | — |
52-Week High | $1.24K | $50.76 |
52-Week Low | $625.65 | $43.26 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.5, down 0.48% today, with technical indicators showing a bullish trend but neutral oscillators. The ETF provides diversified international real estate exposure across 30+ countries with a low 0.12% expense ratio and a 4.6% dividend yield. Recent news highlights its role as a cost-effective diversifier compared to domestic REIT ETFs, though it has lagged in total returns over the past five years.
The outlook remains cautiously optimistic as global real estate transaction volumes are expected to rise over 10% in 2026 amid stabilizing rates. Key opportunities include international diversification and attractive yield, while risks involve currency fluctuations and slower international market recovery compared to U.S. real estate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
